Attached files

file filename
EX-99.1 - EX-99.1 - Zyla Life Sciencesa17-15599_3ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 5, 2017

 


 

Egalet Corporation

(Exact name of Registrant as specified in its charter)

 


 

Delaware

 

001-36295

 

46-357334

(State or Other Jurisdiction
of Incorporation or Organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

600 Lee Road, Suite 100,

Wayne, Pennsylvania 19087

(610) 833-4200

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive
Offices)

 

Not Applicable

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

 

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 



 

Item 8.01 Other Events

 

Offering

 

On July 5, 2017, Egalet Corporation (the “Company”) issued a press release announcing its intention to offer and sell shares of its common stock and accompanying warrants in an underwritten public offering, subject to market conditions and other factors. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

 

At-The-Market” Facility Sales

 

Pursuant to the Company’s Controlled Equity OfferingSM Sales Agreement, dated July 2, 2015, with Cantor Fitzgerald & Co. during the second quarter of 2017, the Company sold an aggregate of 938,556 shares of common stock resulting in net proceeds of approximately $2.8 million.

 

Item 9.01 — Financial Statements and Exhibits

 

(d) Exhibits

 

99.1

 

Press Release, dated July 5, 2017

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: July 5, 2017

EGALET CORPORATION

 

 

 

By:

 

 

/s/ Stan Musial

 

 

Stan Musial

 

 

Chief Financial Officer

 

3